Profiling a Neo‐Antigen‐Driven Immune Response in Healthy Volunteers: A Randomized, Double‐Blind, Placebo‐Controlled Study of the KLH Challenge Model
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.70007 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Micha N Ronner und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Drug Research, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Hemocyanins, Adaptive Immunity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Novel compounds targeting the adaptive immune system are commonly initially investigated in healthy volunteers (HV). HV frequently lack constitutively expressed drug‐target engagement biomarkers, complicating the evaluation of pharmacological activity. The keyhole limpet hemocyanin (KLH) neo‐antigen challenge elicits a controlled immune response in HV and is a potential model for investigating compounds targeting the adaptive immune system. A randomized, double‐blind, placebo‐controlled study in HV was conducted, investigating the effects of repeated immunizations with KLH on Days 1, 15, and 29, followed by intradermal KLH administration on Day 50. Systemically, KLH‐specific antibodies were evaluated. Leukocytes were stimulated ex vivo to determine KLH‐specific responses using ELISpot. Locally, KLH skin response was evaluated 0–48 hours post intradermal administration, using imaging, suction blister fluid analysis, and biopsy analysis. Twelve male HV aged 18–42 years completed the study. KLH antibody levels increased incrementally. ELISpot analyses demonstrated KLH‐specific IFN‐γ and IL‐13 responses. Intradermal KLH injection drove a peak response 24 h after administration, observed as erythema and increased perfusion. Blister fluid analysis showed cell influx (T cells; B cells; monocytes; dendritic cells) at 24 h, largely decreasing at 48 h, as confirmed by immunofluorescent staining of skin biopsies. These findings demonstrate a T‐cell‐mediated response to intradermal KLH that is more rapid than the classical delayed‐type hypersensitivity response. This study highlights the importance of the timing of measurements and combining non‐invasive and invasive biomarkers. The KLH neo‐antigen challenge model presented in this study offers a framework to study the effect of novel immunomodulatory compounds on the adaptive immune system early in clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Human Drug Research, Leiden, The Netherlands.
- Leiden University Medical Center, Leiden, The Netherlands.
- Erasmus University Medical Center, Rotterdam, The Netherlands.
ORCID-Profile: Micha N Ronner, Hendrika W Grievink, Mahdi Saghari, Jacobus Burggraaf, Manon A A Jansen
Zitieren
APA
Ronner, M. N., Grievink, H. W., Saghari, M., Osse, M., van den Bosch, T. P. P., Damman, J., de Kam, M. L., Burggraaf, J., Klarenbeek, N. B., Jansen, M. A. A., & Moerland, M. (2025). Profiling a Neo‐Antigen‐Driven Immune Response in Healthy Volunteers: A Randomized, Double‐Blind, Placebo‐Controlled Study of the KLH Challenge Model. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70007
Vancouver
Ronner MN, Grievink HW, Saghari M, Osse M, van den Bosch TPP, Damman J, et al. Profiling a Neo‐Antigen‐Driven Immune Response in Healthy Volunteers: A Randomized, Double‐Blind, Placebo‐Controlled Study of the KLH Challenge Model. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.70007
BibTeX
@article{Ronner2025,
author = {Ronner, Micha N and Grievink, Hendrika W and Saghari, Mahdi and Osse, Michelle and van den Bosch, Thierry P P and Damman, Jeffrey and de Kam, Marieke L and Burggraaf, Jacobus and Klarenbeek, Naomi B and Jansen, Manon A A and Moerland, Matthijs},
title = {Profiling a Neo‐Antigen‐Driven Immune Response in Healthy Volunteers: A Randomized, Double‐Blind, Placebo‐Controlled Study of the KLH Challenge Model},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.70007}
}
EUVIMED